InvestorLens

PALI — PALISADE BIO INC

Public company

Sign in to save3 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying PALI?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
56
Institutional Conviction
Net distribution · 0 buying vs 0 selling last quarter
34
Macro Tailwind
Macro conditions are mixed for this sector
55
Why? — Evidence & Confidence ▾

No tracked investor changed their PALI position last quarter. Macro conditions are mixed for this sector (Macro Tailwind 55/100 in a Contraction regime).

Supporting evidence
  • +3 tracked investors reported holding PALI at their latest filing
  • +Macro Health is 55/100 in a Contraction regime — historically acceptable for this sectorsource
Contradicting evidence — always shown
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/17/2026.

About PALISADE BIO INC (PALI)

PALISADE BIO INC (PALI) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Steve Cohen (Point72 Asset Management), valued at $25M. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in PALI

50
/100
Mixed Activity
Added / Increased0
Reduced0
Exited0

No recent activity recorded.

Crowded Trade Score™

How many top investors track PALI

20
/100
Emerging Interest
3investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

PALI Ownership Composition

How PALISADE BIO INC is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
100% of tracked value
Institutions
3
tracked investors
Total Reported
$15.1M
combined 13F value
Types1
  • Multi-Strategy / Quant100.0%
Multi-Strategy / Quant(3)
100.0%

Tracked investors currently reporting PALI

  • Steve CohenJun 30, 2026
    Point72 Asset Management
    Shares
    5.3M
    Value
    $11M
    % Portfolio
    0.01%
  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    1M
    Value
    $2.1M
    % Portfolio
    0.00%
  • Izzy EnglanderJun 30, 2026
    Millennium Management
    Shares
    934.2K
    Value
    $2M
    % Portfolio
    0.00%

Recent activity

  • No recent activity.

Frequently asked questions

How many institutional investors hold PALI?
3 tracked institutional investors disclosed a position in PALI (PALISADE BIO INC) in their most recent 13F filing.
Who is the largest institutional holder of PALI?
Steve Cohen, Point72 Asset Management, holds the largest disclosed position in PALI, valued at $25M.
Did institutional ownership of PALI increase or decrease?
Across recent 13F filings, tracked investors recorded 0 new positions, 0 increased, 0 reduced, and 0 fully exited PALI.
Where does this PALI ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.